Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
362-06-011 ISMRM Abstract

The TREM2 R62H variant relates to differences in brain structure across the Alzheimer’s disease continuum

Primary: Neuro - Alzheimer's Disease
Secondary: Neuro - Neuroinflammation
362-06-011 · Neuroimaging Biomarkers of Aging, Vascular Health, and Dementia · Monday, 11 May, 5:05 PM–6:00 PM · Digital Posters Row C
Keywords: Alzheimer's Disease Genetics Cortical thickness Cognitive decline Structural T1 MRI
Accepted
Katherine A Koenig1, James B Leverenz2,3,4, Lynn M Bekris5, Kunio Nakamura6, Mark Lowe 1, Tara DeSilva7
1Diagnostic Radiology, Cleveland Clinic, Cleveland, United States of America
2Geriatric Research, Education, and Clinical Center, VA-Puget Sound Health Care System, United States of America
3Department of Neurology, University of Washington, Seattle, United States of America
4Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, United States of America
5Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States of America
6Biomedical Engineering, Cleveland Clinic Research, Cleveland, United States of America
7Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, United States of America
Presenting Author: Mark Lowe

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405. doi: 10.1016/s1474-4422(15)70016-5. [doi]
2. Cuyvers, E., Bettens, K., Philtjens, S., et al. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging 35, 726 e11-9 (2014). doi: https://doi.org/10.1016/j.neurobiolaging.2013.09.009. [doi]
3. Tsui JSM, Au DM, Uhm H, et al. The TREM2 H157Y variant is associated with more severe neurodegeneration in Alzheimer's disease and altered immune-related processes. Alzheimers Dement. 2025 Sep;21(9):e70586. doi: 10.1002/alz.70586. [doi]
4. Kim B, Suh E, Nguyen AT, Prokop S, Mikytuck B, Olatunji OA, et al. TREM2 risk variants are associated with atypical Alzheimer’s disease. Acta Neuropathol. 2022;144:1085–102.
5. Dijkstra JIR, Vermunt L, Venkatraghavan V, et al. TREM2 risk variants and associated endophenotypes in alzheimer's disease. Alzheimers Res Ther. 2025 Mar 6;17(1):57. doi: 10.1186/s13195-025-01700-2. [doi]
6. Prokop S, Miller KR, Labra SR, et al. Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer’s disease patient brain samples. Acta Neuropathol. 2019;138:613–30. doi: 10.1007/s00401-019-02048-2. [doi]
7. Luis EO, Ortega-Cubero S, Lamet I, Razquin C, Cruchaga C, Benitez BA, Lorenzo E, Irigoyen J; Alzheimer's Disease Neuroimaging Initiative (ADNI); Pastor MA, Pastor P. Frontobasal gray matter loss is associated with the TREM2 p.R47H variant. Neurobiol Aging. 2014 Dec;35(12):2681-2690. doi: 10.1016/j.neurobiolaging.2014.06.007. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/362-06-011